[1] |
HUA Zhihui, LIU Dong, ZHANG Jiandong, CAI Siyu, GE Chunli, CHEN Nan, QI Qi.
Clinical evaluation of the efficacy against helicobacter pylori by amoxicillin from volume-based procurement and potassium amoxicillin clavulanate
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1061-1066.
|
[2] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[3] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[4] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[5] |
WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai.
Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
|
[6] |
ZHANG Qiang, ZHENG Huajun, LI Quan.
Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
|
[7] |
ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi.
Interactions and clinical significance of gut microbiota and levothyroxine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
|
[8] |
CHEN Qian, WANG Yafeng, DUO Delong, CHANG Ya'e, YAN Yingjun, DUAN Kunkun.
Trigliptin succinate have an effect on gut microbiota of type 2 diabetic mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 15-24.
|
[9] |
LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao.
Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
|
[10] |
LI Wei, HU Jiali, WANG Kai, HE Yijing.
Research progress and prospect of immunotherapy in the treatment of melanoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
|
[11] |
WANG Yaya, CHU Zixuan, YANG Junling, Olajide E. Olaleye, HE Rongrong, LI Muzi, CHENG Chen, LI Chuan.
Potential health benefits of resveratrol: a pharmacokinetics-caused conundrum
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 931-954.
|
[12] |
WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru.
Applications of BGUSs inhibition in tumor prevention and chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
|
[13] |
ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng.
Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
|
[14] |
JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi.
AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
|
[15] |
Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning.
Research progress in clinical trials of targeted drugs for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
|